Abstract
Several autoimmune and chronic inflammatory conditions have been consistently linked with an increased risk of hematologic malignancies. Although ankylosing spondylitis (AS) is a chronic inflammatory disease, previous studies have demonstrated that it is not associated with an increase in risk of malignant lymphomas. Cases of AS accompanied by hematologic malignancies such as multiple myeloma, chronic myelogenous leukemia, and Hodgkin's disease have been reported. In Korea, AS with non-Hodgkin's lymphoma or follicular lymphoma has not been reported. We experienced a 38-year-old male who had been diagnosed with follicular lymphoma with bone metastasis, who achieved complete remission after having been treated with chemotherapy, developed new inflammatory back pain. An MRI of his hip showed an active inflammation of the left sacroiliac joint and a positive HLA-B27. The patient was diagnosed with AS and was treated with naproxen, which improved the pain in his back and buttock.
References
1. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008; 111:4029–38.
2. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis. 2006; 65:1184–7.
3. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas–an update. J Intern Med. 2008; 264:514–27.
4. Choi WH, Ji EH, Lee JH, Kim SW, Min JS, Park HW, et al. A case of ankylosing spondylitis accompanied by chronic myelogenous leukemia. J Korean Rheum Assoc. 2010; 17:417–21.
5. Moon HI, Chang HJ, Kim JE, Ko HY, Ann SH, Min CK. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009; 44:182–7.
6. Park DJ, Moon SD, Byun BH, Park SH, Lee SH, Cho CS, et al. Hodgkin's disease developed in a patient with ankylosing spondylitis. Korean J Med. 1995; 48:531–5.
7. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64:1414–20.
8. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165:2337–44.
9. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54:692–701.
10. Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol. 2001; 115:320–2.
11. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116:3724–34.
12. Chang MH, Kim SJ, Kim K, Oh SY, Lee DH, Huh J, et al. Clinical features and treatment outcomes of adult B-and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. Leuk Lymphoma. 2009; 50:1119–25.
13. Calin A. Back pain: mechanical or inflammatory? Am Fam Physician. 1979; 20:97–100.
14. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27:361–8.
15. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010; 62:1290–7.